Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer

Neuregulin 1 (NRG1), a ligand for HER3 and HER4 receptors, is secreted by both pancreatic tumor cells (PC) and cancer-associated fibroblasts (CAFs), the latter representing the most abundant compound of pancreatic stroma. This desmoplastic stroma contributes to Pancreatic Ductal Adenocarcinoma (PDAC) aggressiveness and therapeutic failure by promoting tumor progression, invasion and resistance to chemotherapies. In the present work, we aimed at disrupting the complex crosstalk between PC and CAF in order to prevent tumor cell proliferation.

Source: Cancer Letters - June 20, 2018 Category: Cancer & Oncology Authors: Charline Ogier, Pierre-Emmanuel Colombo, Corinne Bousquet, Lucile Canterel-Thouennon, Pierre Sicard, V éronique Garambois, Gaëlle Thomas, Nadège Gaborit, Marta Jarlier, Nelly Pirot, Martine Pugnière, Nadia Vie, Céline Gongora, Pierre Martineau, Bruno Tags: Original Articles Source Type: research